ArticleOncology letters2017
The effects of hyperoside on apoptosis and the expression of Fas/FasL and survivin in SW579 human thyroid squamous cell carcinoma cell line.
Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Quantitative assessment of the relationship between Fas/FasL genes polymorphisms and head and neck cancer risk.Medicine · 2018Pooled it
- Hyperoside induces ferroptosis in chronic myeloid leukemia cells by targeting NRF2.Molecular medicine (Cambridge, Mass.) · 2024Article
- Effects of Strawberry Tree (Toxics · 2024Article
- Review
- Potential Implications of Hyperoside on Oxidative Stress-Induced Human Diseases: A Comprehensive Review.Journal of inflammation research · 2023Review
- CDCA8 Contributes to the Development and Progression of Thyroid Cancer through Regulating CDK1.Journal of Cancer · 2022Article
- Lactonic sophorolipid-induced apoptosis in human HepG2 cells through the Caspase-3 pathway.Applied microbiology and biotechnology · 2021Article
- Hyperoside Induces Breast Cancer Cells Apoptosis via ROS-Mediated NF-κB Signaling Pathway.International journal of molecular sciences · 2019Article
- HDAC1 and HDAC2 Double Knockout Triggers Cell Apoptosis in Advanced Thyroid Cancer.International journal of molecular sciences · 2019Article
- The Possible Mechanisms of HSV-TK/Hyperthermia Combined with 131I-antiAFPMcAb-GCV Nanospheres to Treat Hepatoma.Analytical cellular pathology (Amsterdam) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated the effects of hyperoside on apoptosis of human thyroid squamous cell carcinoma cells (SW579) and measured changes in the expression of known apoptosis regulatory players Fas/FasL and survivin. SW579 cells were treated with increasing concentrations of hyperoside. The cell proliferation inhibition rate was measured by MTT assay. Morphological changes in cells were observed by microscopy. Cell apoptosis was detected by flow cytometry using AV-PI double staining. The normalized expression levels of Fas and FasL mRNAs were detected by reverse transcription quantitative PCR (RT-qPCR), and the expression of the survivin protein was detected by western blotting. Our results showed that hyperoside significantly inhibited the activity of SW579 cells; obvious morphological changes were observed and apoptosis was induced in a dose-dependent manner. Hyperoside was shown to upregulate the expression of Fas and FasL mRNAs and downregulate the expression of the survivin protein. The results suggested that hyperoside can induce the apoptosis of the SW579 human thyroid squamous cell carcinoma cell line, and partially by upregulating the expression of Fas and FasL mRNAs and downregulating the expression of survivin protein in the process of apoptosis. Further studies on the use of hyperoside against cancer cells are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.